Compare
Arrowhead Pharmaceuticals, Inc. vs Zai Lab Ltd vs Nature's Sunshine Products Inc vs Innoviva, Inc.
| Latest fiscal year | Arrowhead Pharmaceuticals, Inc. ARWR | Zai Lab Ltd ZLAB | Nature's Sunshine Products Inc NATR | Innoviva, Inc. INVA |
|---|---|---|---|---|
| Year ended | 2026-09-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $450.82M | $457.18M | $480.14M | $411.33M |
| Revenue growth (YoY) | -45.6% | +15.0% | +5.7% | +14.7% |
| Gross margin | n/a | 58.3% (computed) | 72.4% | 74.8% |
| Operating margin | -156.9% | -50.2% | 5.2% | 39.8% |
| Net margin | -159.1% | -38.4% | 4.3% | 65.9% |
| Net income | -$717.13M | -$175.54M | $20.45M | $271.17M |
| EPS (Diluted) | -$5.11 | -$0.16 | $1.06 | $3.30 |
| Operating cash flow | -$271.95M | -$150.79M | $35.32M | $196.93M |
| Free cash flow | -$283.94M | -$158.89M | $28.84M | $195.80M |
| Cash & equivalents | n/a | $679.57M | $93.89M | $550.94M |
| Total assets | $1.74B | $1.17B | $261.15M | $1.64B |
| Total liabilities | n/a | $456.88M | $99.59M | n/a |
| Shareholders' equity | $50.50M | $715.50M | $161.55M | $1.17B |
| Return on year-end equity | n/m | -24.5% | 12.7% | 23.1% |
| Shares outstanding | 141.29M | 1.11B | 17.51M | 74.64M |
Revenue, most recent five fiscal years
| Fiscal year | Arrowhead Pharmaceuticals, Inc. | Zai Lab Ltd | Nature's Sunshine Products Inc | Innoviva, Inc. |
|---|---|---|---|---|
| Latest | $450.82M Ended 2026-09-30 | $457.18M Ended 2025-12-31 | $480.14M Ended 2025-12-31 | $411.33M Ended 2025-12-31 |
| 1 year earlier | $829.45M Ended 2025-09-30 | $397.61M Ended 2024-12-31 | $454.36M Ended 2024-12-31 | $358.71M Ended 2024-12-31 |
| 2 years earlier | $3.55M Ended 2024-09-30 | $266.72M Ended 2023-12-31 | $445.32M Ended 2023-12-31 | $310.46M Ended 2023-12-31 |
| 3 years earlier | $240.74M Ended 2023-09-30 | $212.67M Ended 2022-12-31 | $421.91M Ended 2022-12-31 | $331.34M Ended 2022-12-31 |
| 4 years earlier | $243.23M Ended 2022-09-30 | $144.10M Ended 2021-12-31 | $444.08M Ended 2021-12-31 | $391.87M Ended 2021-12-31 |